Intracerebral Injection of Extracellular Vesicles from Mesenchymal Stem Cells Exerts Reduced Aβ Plaque Burden in Early Stages of a Preclinical Model of Alzheimer's Disease
| Autor: | Genni Desiato, Maria Luisa Malosio, Matteo Tamborini, Marco Rasile, Sonia Mazzitelli, Paolo Swuec, Achille Anselmo, Chiara A. Elia, Silvia Coco, Sara Marchetti, Michela Matteoli, Francesca Clemente |
|---|---|
| Přispěvatelé: | Elia, C, Tamborini, M, Rasile, M, Desiato, G, Marchetti, S, Swuec, P, Mazzitelli, S, Clemente, F, Anselmo, A, Matteoli, M, Luisa Malosio, M, Coco, S |
| Rok vydání: | 2019 |
| Předmět: |
Male
Hippocampus Context (language use) Plaque Amyloid Disease Aβ plaques Mesenchymal Stem Cell Transplantation Article Extracellular Vesicles Mice Alzheimer Disease ddc:570 Neurites Medicine Animals lcsh:QH301-705.5 Neprilysin Cerebral Cortex Neocortex Amyloid beta-Peptides SMI biology business.industry dystrophic neuritis Mesenchymal stem cell Brain bone marrow mesenchymal stem cells dystrophic neuriti Mesenchymal Stem Cells General Medicine Cortex (botany) APPswe/PS1dE9 AD mice Mice Inbred C57BL Disease Models Animal medicine.anatomical_structure lcsh:Biology (General) bone marrow mesenchymal stem cell biology.protein Female extracellular vesicle business Neuroscience Alzheimer’s disease Neurotrophin |
| Zdroj: | Cells Cells 8(9), 1059 (2019). doi:10.3390/cells8091059 Volume 8 Issue 9 Cells, Vol 8, Iss 9, p 1059 (2019) |
| ISSN: | 2073-4409 |
| Popis: | Bone marrow Mesenchymal Stem Cells (BM-MSCs), due to their strong protective and anti-inflammatory abilities, have been widely investigated in the context of several diseases for their possible therapeutic role, based on the release of a highly proactive secretome composed of soluble factors and Extracellular Vesicles (EVs). BM-MSC-EVs, in particular, convey many of the beneficial features of parental cells, including direct and indirect &beta amyloid degrading-activities, immunoregulatory and neurotrophic abilities. Therefore, EVs represent an extremely attractive tool for therapeutic purposes in neurodegenerative diseases, including Alzheimer&rsquo s disease (AD). We examined the therapeutic potential of BM-MSC-EVs injected intracerebrally into the neocortex of APPswe/PS1dE9 AD mice at 3 and 5 months of age, a time window in which the cognitive behavioral phenotype is not yet detectable or has just started to appear. We demonstrate that BM-MSC-EVs are effective at reducing the A&beta plaque burden and the amount of dystrophic neurites in both the cortex and hippocampus. The presence of Neprilysin on BM-MSC-EVs, opens the possibility of a direct &beta amyloid degrading action. Our results indicate a potential role for BM-MSC-EVs already in the early stages of AD, suggesting the possibility of intervening before overt clinical manifestations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |